Abstract Background and Aims Chimeric antigen receptor T cell therapy (CAR-T) has improved the prognosis of patients with refractory hematologic malignancies. The most important toxicities are cytokine release syndrome (CRS), where interleukin 6 (IL-6) plays a major role, immune effector cell-associated neurotoxicity (ICANS). A low incidence acute kidney injury (AKI) high frequency electrolyte ...